Inspection Pilot May be Permanent as FDA Expands AI-Driven Oversight

FDA’s newly announced pilot program for one-day inspectional assessments (see earlier story) may signal a long-term shift toward faster, AI-assisted oversight of regulated facilities, according to an analysis published by law firm King & Spalding.

FDA formally announced the pilot program on 5/6, though the agency said it quietly began conducting the abbreviated inspections in April. The one-day assessments are intended to supplement, rather than replace, traditional multi-day inspections and are aimed primarily at lower-risk facilities.

According to FDA, the shorter inspections are designed to expand surveillance coverage and allow investigators to assess more facilities without reducing regulatory rigor. The pilot spans multiple FDA-regulated sectors, including human and animal foods, biologics, drugs, medical devices, and clinical research programs.

FDA has already conducted 46 one-day assessments, with most resulting in “No Action Indicated” classifications, meaning inspectors did not issue Form FDA 483 observations. However, the agency said some inspections were expanded into longer, traditional inspections after investigators identified significant concerns. The pilot is scheduled to continue through fiscal year 2026.

In its analysis, King & Spalding said the initiative appears to be closely tied to FDA’s growing use of artificial intelligence tools to prioritize inspection targets. During remarks at the Food and Drug Law Institute annual conference, then-FDA commissioner Marty Makary reportedly said the agency is using AI to help identify facilities suitable for one-day inspections.

The law firm pointed to FDA’s recently upgraded internal AI platform, ELSA 4.0, which the agency says can analyze quality metrics, deviations, corrective and preventive actions (CAPAs), and other compliance signals that may not be readily apparent to human investigators.

King & Spalding said ELSA likely evaluates inspection histories, operational risks, manufacturing complexity, and geographic trends to identify facilities considered lower risk. Factors expected to influence selection include prior inspection classifications, Warning Letter history, sterile versus nonsterile manufacturing operations, and manufacturing location.

The analysis suggested that facilities in countries such as China and India could face higher scrutiny because of historical trends involving “official action indicated” classifications and Warning Letters.

FDA has stressed that the one-day assessments are limited to surveillance activities and will not replace pre-approval, pre-license, or for-cause inspections, which will continue to follow traditional multi-day formats. Higher-risk or more complex facilities also are expected to remain subject to conventional inspections.

The law firm said the abbreviated inspections likely will be paired with other remote oversight tools FDA has increasingly adopted in recent years, including remote regulatory assessments and livestream video evaluations. Those approaches may allow investigators to review records before arriving onsite, enabling them to focus intensely on facility conditions during the compressed inspection window.

King & Spalding said manufacturers hoping to avoid escalation from a one-day assessment into a longer inspection will need to demonstrate strong compliance systems, rapid document retrieval capabilities, and a visible quality-focused culture.

The firm noted that investigators conducting condensed inspections are unlikely to tolerate delays in producing records or locating personnel responsible for quality oversight. Initial facility conditions, equipment cleanliness, personnel hygiene, and data integrity practices are expected to receive heightened scrutiny during the brief onsite visits.

The analysis also suggested the program could become permanent as FDA continues to face staffing shortages among investigators and inspectors.

FDA associate commissioner for inspections and investigations Elizabeth Miller has said the agency plans to analyze operational metrics, escalation rates, risk signals, and investigator feedback from the pilot to determine whether the approach should become part of FDA’s broader inspection strategy.